Read by QxMD icon Read

Journal of Medical Economics

Scott D Grosse, Kurt V Krueger, Jamison Pike
BACKGROUND: Human-capital based lifetime productivity estimates are frequently used in cost-of-illness (COI) analyses and, less commonly, in cost-effectiveness analyses (CEAs). Previous US estimates assumed that labor productivity and real earnings both grow by 1% per year. OBJECTIVES: We present estimates of annual and lifetime productivity for 2016 using data from the American Community Survey, the American Time Use Survey, and the Current Population Survey and with varying assumptions about real earnings growth...
November 2, 2018: Journal of Medical Economics
Nazila Yousefi, Saeed Taheri, Mohammad Ali Sahraian
BACKGROUND: Alemtuzumab and natalizumab are approved as second-line therapies for relapsing-remitting multiple sclerosis (RRMS) patients in Iran who have shown an inadequate response to other disease-modifying therapy (DMT). In the absence of head-to-head trials, evaluations based on decision analytic modeling may be a suitable alternative to compare alemtuzumab and natalizumab in RRMS. PURPOSE: To evaluate the cost-effectiveness of alemtuzumab compared with natalizumab in RRMS in Iran, based on an indirect comparison of clinical trial data...
October 31, 2018: Journal of Medical Economics
(no author information available yet)
No abstract text is available yet for this article.
October 31, 2018: Journal of Medical Economics
Carl V Asche, Simon Dagenais, Amiee Kang, Jinma Ren, Brian T Maurer
AIMS: Postsurgical pain experienced by patients undergoing total knee arthroplasty (TKA) can be severe. Enhanced recovery after surgery programs incorporating multimodal analgesic regimens have evolved in an attempt to improve patient care while lowering overall costs. We examined clinical and economic outcomes in hospitals using liposomal bupivacaine (LB) for pain control following TKA. METHODS: This retrospective observational study utilized hospital chargemaster data from the Premier Healthcare Database from January 2011 through April 2017 for the 10 hospitals with the highest number of primary TKA procedures using LB...
October 31, 2018: Journal of Medical Economics
Michael S Broder, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan, Irina Yermilov
AIMS: This study explored the association between medication adherence to oral atypical antipsychotics (AAP) and both psychiatric hospitalization and associated costs in bipolar I disorder (BD-I) in a real-world setting. MATERIALS AND METHODS: This retrospective study used the Truven Health MarketScan® Medicaid, Commercial, and Medicare Supplemental claims Databases. Adults were identified if they had BD-I and initiated an AAP treatment during the study identification period (7/1/15-6/30/16 for Medicaid, 7/1/15-3/31/16 for Commercial and Medicare Supplemental) and had ≥6-month continuous enrollment before (baseline) and after (follow-up) the first day of treatment...
October 31, 2018: Journal of Medical Economics
Thomas E Delea, Arati Sharma, Aaron Grossman, Caitlin Eichten, Keenan Fenton, Neil Josephson, Akshara Richhariya, Alison J Moskowitz
OBJECTIVE: The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness of A + AVD from a US healthcare payer perspective. METHODS: The incremental cost-effectiveness ratio (ICER), defined as the incremental costs per quality-adjusted life year (QALY) gained, was estimated using a non-homogenous semi-Markov cohort model with health states defined on progression following frontline treatment, and for those with progression, receipt of autologous stem-cell transplant (ASCT), and progression after ASCT...
October 30, 2018: Journal of Medical Economics
Atsuyuki Igarashi, Ataru Igarashi, Christopher N Graham, Isabelle Gilloteau, Yumiko Tani
AIM: To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment (using different frequencies of drug purchase) perspectives. METHODS: A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was developed...
October 26, 2018: Journal of Medical Economics
Mwangi J Murage, David M Kern, Lawrence Chang, Kalyani Sonawane, William N Malatestinic, Ralph A Quimbo, Steven R Feldman, Talia M Muram, Andre B Araujo
AIM: Characterize treatment patterns of psoriasis patients in a large U.S. managed care database. MATERIALS AND METHODS: Adults with newly diagnosed psoriasis were identified from 07/03/2006-08/31/2014. Patients had continuous enrollment with medical and pharmacy benefits for ≥6 months prior to and ≥1 year following the index date. Index date was the point at which any of the following inclusion criteria were satisfied: first psoriasis diagnosis by a dermatologist, ≥2 psoriasis diagnoses ≥30 days apart, or a diagnosis of psoriasis followed by a claim for psoriasis therapy...
October 25, 2018: Journal of Medical Economics
Khachen Kongpakwattana, Piyameth Dilokthornsakul, Charungthai Dejthevaporn, Oraluck Pattanaprateep, Nathorn Chaiyakunapruk
AIMS: Due to the lack of studies evaluating compliance or persistence with Alzheimer's Disease (AD) treatment outside High-Income Countries (HICs), this study aimed to assess compliance, persistence, and factors associated with non-compliance and non-persistence by utilizing existing "real-world" information from multiregional hospital databases in Thailand. MATERIALS AND METHODS: Study subjects were retrospectively identified from databases of five hospitals located in different regions across Thailand...
October 24, 2018: Journal of Medical Economics
Natalia M Flores, Javier Nuevo, Alyssa B Klein, Scott Baumgartner, Robert Morlock
AIM: To evaluate the burden of uncontrolled gout by examining estimated costs and cost drivers. MATERIALS AND METHODS: Data from the 2012 and 2013 US National Health and Wellness Survey (NHWS; 2012 NHWS, n = 71,157 and 2013 NHWS, n = 75,000) were utilized in this study. Based on self-reported gout diagnosis and gout symptoms, respondents were categorized into three groups: controlled gout (n = 344), uncontrolled gout (n = 2,215), and non-gout controls (n = 126,360)...
October 24, 2018: Journal of Medical Economics
Xiaoyu Xi, Ennan Wang, Qianni Lu, Piaopiao Chen, Tian Wo, Kammy Tang
AIMS: This study analyzed discrepancies in the quantity of medical services supplied by physicians under different payment systems for patients with different health statuses and illnesses by means of a field experiment. METHODS: Based on the laboratory experiment of Heike Hennig-Schmidt (2011), we designed a field experiment to examine fee-for-service (FFS), capitation (CAP) and diagnosis-related group (DRG) payment systems. We replaced medical students with 220 physicians as experimental subjects, which more closely reflected the clinical choices made by physicians in the real world...
October 23, 2018: Journal of Medical Economics
Ron Goeree, Sima Chiva-Razavi, Praveen Gunda, Minal Jain, Steffen M Jugl
INTRODUCTION: To assess the cost-effectiveness of interleukin (IL)-17A inhibitor secukinumab versus the currently licensed biologic therapies in ankylosing spondylitis (AS) patients from a Canadian healthcare system perspective. METHODS: A decision analytic model (semi-Markov) evaluated the cost-effectiveness of secukinumab 150mg compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar in a biologic-naïve population, over 60 years of time horizon (lifetime)...
October 22, 2018: Journal of Medical Economics
Eli F Kelley, Eric M Snyder, Nimer S Alkhatib, Scott C Snyder, Ryan Sprissler, Thomas P Olson, Monica K Akre, Ivo Abraham
AIMS: Hypertension is the strongest modifiable risk factor for cardiovascular disease, affecting 80 million individuals in the US and responsible for ∼360,000 deaths, at total annual costs of $93.5 billion. Antihypertension therapies guided by single genotypes are clinically more effective and may avert more adverse events than the standard of care of layering anti-hypertensive drug therapies, thus potentially decreasing costs. This study aimed to determine the economic benefits of the implementation of multi-gene panel guided therapies for hypertension from the payer perspective within a 3-year time horizon...
October 22, 2018: Journal of Medical Economics
Lin Liang, David Bin-Chia Wu, Mohamed Ismail Abdul Aziz, Raymond Wong, David Sim, Kui Toh Gerard Leong, Yong Quek Wei, Doreen Tan, Kwong Ng
No abstract text is available yet for this article.
October 17, 2018: Journal of Medical Economics
Joshua A Roth, Sean D Sullivan, Vincent W Lin, Aasthaa Bansal, Anna G Purdum, Lynn Navale, Paul Cheng, Scott D Ramsey
PURPOSE: Axicabtagene ciloleucel (axi-cel) was recently approved for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL) following two or more prior therapies. As the first CAR T-cell therapy available for adults in the US, there are important questions about clinical and economic value. The objective of this study was to assess the cost-effectiveness of axi-cel compared to salvage chemotherapy using a decision model and a US payer perspective. MATERIALS AND METHODS: A decision model was developed to estimate life years (LYs), quality-adjusted life years (QALYs), and lifetime cost for adult patients with R/R LBCL treated with axi-cel vs salvage chemotherapy (R-DHAP)...
October 16, 2018: Journal of Medical Economics
Jui-Hua Tsai, Ann O Scheimann, Shawn E McCandless, Theresa V Strong, John F P Bridges
OBJECTIVES: Prader-Willi syndrome (PWS) is a rare genetic disorder associated with varying degrees of hyperphagia, obesity, intellectual disability, and anxiety across the affected individuals' lifetimes. This study quantified caregiver priorities for potential treatment endpoints to identify unmet needs in PWS. METHODS: The authors partnered with the International Consortium to Advance Clinical Trials for PWS (PWS-CTC) and a diverse stakeholder advisory board to develop a best-worst scaling instrument...
October 16, 2018: Journal of Medical Economics
Samuel Large, Robert Hettle, Arun Balakumaran, Elise Wu, Rebekah H Borse
AIMS: Patients with classical Hodgkin's lymphoma (cHL) who have relapsed after or are ineligible for autologous stem cell transplantation (ASCT) have limited treatment options and generally a poor prognosis. Pembrolizumab was recently approved in the United States for the treatment of such patients having demonstrated clinical benefit and tolerability in relapsed/refractory cHL; however, the cost-effectiveness of pembrolizumab in this population is currently unknown. MATERIALS AND METHODS: A three-state Markov model (progression-free [PF], progressed disease, and death) was developed to assess the cost-effectiveness of pembrolizumab (200 mg) versus brentuximab vedotin (BV; 1...
October 10, 2018: Journal of Medical Economics
Kaoru Yamabe, Ryan Liebert, Natalia Flores, Chris Pashos
AIMS: This study aimed to characterize the burden of Parkinson's disease (PD) by examining health-related quality-of-life (HRQoL), impairments to work productivity and daily activities, healthcare resource use, and associated costs among Japanese patients with PD. MATERIALS AND METHODS: This retrospective cross-sectional study used data from the 2009-2014 Japan National Health and Wellness Survey (NHWS) (n = 144,692). HRQoL (Short Form 36-Item Health Survey version 2), impairments to work productivity and daily activities (Work Productivity and Activity Impairment Questionnaire), healthcare resource utilization, and annual costs were compared between respondents with PD (n = 133) and controls without PD (n = 144,559)...
October 1, 2018: Journal of Medical Economics
Martin Cloutier, Mallik Greene, Maëlys Touya, Patrick Gagnon-Sanschagrin, Annie Guerin
AIMS: Antipsychotic medications are associated with an increased risk of hyperprolactinemia, but differ in their propensity to cause this complication. This study aimed to assess the economic burden of hyperprolactinemia, and to compare its risk among adult patients using atypical antipsychotics (AAs) with a mechanism of action associated with no/low vs high/moderate prolactin elevation. METHODS: This retrospective cohort study was based on US Commercial and Medicaid claims databases...
September 26, 2018: Journal of Medical Economics
David N van der Goes, Richard Santos
BACKGROUND: Private health insurance (PHI) represents the largest source of insurance for Americans. Hispanic Americans have one of the lowest rates of PHI coverage. The largest group in the US Hispanic population are Mexican Americans; they account for about two in every three Hispanics. One in every three Mexican Americans aged 64 years and under did not have health insurance coverage. Mexican Americans have the most unfavorable health insurance coverage of any population group in the nation...
September 25, 2018: Journal of Medical Economics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"